Celsion Corporation announced that On December 30, 2021, Dr. Andreas Voss, a Class III member of the Board of Directors will retire from the Company's Board effective December 31, 2021. Dr. Voss has served as member of the Science & Technology Committee of the Board. In addition to his Board position, Dr. Voss also acted as a strategic advisor to the Company's Chief Executive Officer during 2020 to 2021. Through this advisory role, Dr. Voss accepted the position of Managing Director of Celsion GmbH, a wholly owned subsidiary of the Company. In this role, Dr. Voss has elected to devote his time to providing strategy, direction, and general management to Celsion GmbH and has concluded that the time necessary to do so would interfere with the demands of the Company's Board. Dr. Voss intends to retire for these reasons and not because of any disagreement with management or the Board relating to the Company's operations, policies or practices. Dr. Voss's current term as a Class III director was scheduled to end at the Company's 2022 Annual Meeting of Stockholders.
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the bodyâs natural mechanisms across an array of human diseases. The Company is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit a strong immunological response. The third modality, FixPlas, concerns the application of Imunonâs DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, IndiPlas, is in the discovery phase and is focused on the development of personalized cancer vaccines, or neoepitope cancer vaccines. Its lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer.